The bad-ad watchdog issued an untitled letter to drugmaker Duchesnay in November.
FDA panel briefing documents indicate concern remains over bladder cancer, as the drug dapagliflozin undergoes a second review Thursday.
The company says Docnet is more than a social site—it's a hub that merges networking, research and financial (as in Sunshine) resources.
The drug is priced at $28,000 a month, before add-ons like ribivarin and (possibly) interferon.
Fundamental flaws in our current business model must be fixed if our industry is to stay vital and competitive into the next decade.
Genentech has gone out of its way to keep doctors choosing Lucentis over cheaper Avastin, the paper reports, and they have little incentive to do otherwise.
The company released two financial scenarios. The key is generic Copaxone.
People asked, experts answered.
Click on the image above to see a gallery of images from the 2013 MM&M Awards dinner
Missed MM&M's recent Skill Sets Live event on Multi-Screen Marketing? We're now giving you a second chance to get up to speed! Click here to access this insightful e-book with all the key take-aways.